Avricore Health (AVCRF) EBIT Margin (2009 - 2025)

Avricore Health has disclosed EBIT Margin across 16 years of filings, most recently posting 1012.72% for Q3 2025.

• In Q3 2025, EBIT Margin fell 99808.0% year-over-year to 1012.72%; the TTM figure through Sep 2025 stood at 65.26% (down 6755.0% YoY), while the FY2025 annual figure was 259.13%, down 26183.0% from the prior year.
• EBIT Margin grew to 1012.72% in Q3 2025, from 1651.97% in the prior quarter.
• Over the last five years, EBIT Margin for AVCRF reached as high as 15.35% in Q1 2023 and fell as low as 1651.97% in Q2 2025.
• The 5-year median for EBIT Margin is 37.52% (2022), against an average of 292.94%.
• Annual changes were most pronounced in 2022 — EBIT Margin surged 121135 bps — and 2025, when it sank 165714 bps.
• A 5-year view of EBIT Margin shows it stood at 306.89% in 2021, then surged by 92 bps to 24.43% in 2022, then soared by 121 bps to 5.07% in 2023, then tumbled by 389 bps to 14.64% in 2024, then sank by 6816 bps to 1012.72% in 2025.
• According to Business Quant data, EBIT Margin over the past three periods registered 1012.72%, 1651.97%, and 17.48% for Q3 2025, Q2 2025, and Q1 2025 respectively.